USA flag logo/image

An Official Website of the United States Government

Company Information:

Company Name:
BEXION PHARMACEUTICALS, INC.
Address:
632 Russell St
Covington, KY 41011-
Phone:
N/A
URL:
N/A
EIN:
120846523
DUNS:
782233501
Number of Employees:
N/A
Woman-Owned?:
No
Minority-Owned?:
No
HUBZone-Owned?:
No

Commercialization:

Has been acquired/merged with?:
N/A
Has had Spin-off?:
N/A
Has Had IPO?:
N/A
Year of IPO:
N/A
Has Patents?:
N/A
Number of Patents:
N/A
Total Sales to Date $:
$ 0.00
Total Investment to Date $
$ 0.00
POC Title:
N/A
POC Name:
N/A
POC Phone:
N/A
POC Email:
N/A
Narrative:
N/A

Award Totals:

Program/Phase Award Amount ($) Number of Awards
SBIR Phase I $518,409.00 3
SBIR Phase II $4,368,595.00 2

Award List:

A novel biotherapeutic treatment for prostate cancer

Award Year / Program / Phase:
2007 / SBIR / Phase I
Award Amount:
$145,306.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): The American Cancer Society estimated a total of 1,372,910 new cancer cases and 570,280 cancer deaths in the U. S. in 2005. The National Cancer Institute solicits research proposals to develop cancer treatments via the Small Business Innovation Research funding… More

SapC-DOPS Nanovesicles for Treating Glioblastoma Multiforme

Award Year / Program / Phase:
2008 / SBIR / Phase I
Award Amount:
$273,138.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): We are proposing to develop a new treatment for targeting and eliminating glioblastoma multiforme (GBM, high grade glioma), a deadly and invasive brain tumor with no effective treatment. Of the 12,000 patients expected to be diagnosed with GBM this year, most… More

A Novel Biotherapeutic Treatment for Pancreatic Cancer

Award Year / Program / Phase:
2008 / SBIR / Phase I
Award Amount:
$99,965.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): Carcinoma of the pancreas is the 4th leading cause of cancer deaths. The American Cancer Society has estimated 37,170 new cases and 33,370 deaths in 2007. The cancer generally develops without early symptoms and most pa tients present to treating physicians with… More

SapC-DOPS nanovesicles for Treating Glioblastoma Multiforme

Award Year / Program / Phase:
2010 / SBIR / Phase II
Award Amount:
$1,511,323.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): Our goal is to develop a new molecular entity with a novel mechanism of action for targeting and eliminating glioblastoma multiforme (GBM, high grade glioma), a deadly and invasive brain tumor with no effective trea tment. Of the 12,000 patients expected to… More

SapC-DOPS Nanovesicles for Treating Glioblastoma Multiforme

Award Year / Program / Phase:
2013 / SBIR / Phase II
Award Amount:
$2,857,272.00
Agency:
HHS
Principal Investigator:
Kevin Xu – 513-807-0574
Abstract:
DESCRIPTION (provided by applicant): Our goal is to develop a new molecular entity with a novel mechanism of action for targeting and eliminating glioblastoma multiforme (GBM, high grade glioma), a deadly and invasive brain tumor with no effective treatment. Of the 12,000 patients expected to be… More